论文信息 - Addition of Herceptin (humanized anti-HER2 antibody) to first line chemotherapy for HER2 overexpressing metastatic breast cancer (HER2+/MBC) markedly increases anti-cancer activity: a randomised multinational controlled phase III trial - 字舞流文

Addition of Herceptin (humanized anti-HER2 antibody) to first line chemotherapy for HER2 overexpressing metastatic breast cancer (HER2+/MBC) markedly increases anti-cancer activity: a randomised multinational controlled phase III trial

T. Fleming | L. Norton | J. Baselga | W. Eiermann | S. Shak | D. Slamon | J. Wolter | V. Paton | A. Bajamonde | Virginia Paton | Dennis J. Slamon | J. Baselga | S. Leyland-Jones | S. Shak | A. Bajamonde | T. Fleming | W. Eiermann | Janet Wolter | L. Norton | S. Leyland-Jones